The effect of blueberries on blood vessel function, inflammation and oxidative stress in older people

Evaluation of blueberry polyphenols absorption and their role in modulation of vascular function, inflammation and oxidative stress in a group of older subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18262533

Enrollment

Registered

2021-05-07

Start date

2021-05-10

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular function in older people Circulatory System

Interventions

Based on a computer randomization plan, participants are randomized to receive the two study products in a random order. The trial is divided into two phases. For the first phase of t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age =60 years old 2. Absence of major diseases

Exclusion criteria

Exclusion criteria: 1. Subjects with allergies or other adverse reaction to the ingestion of blueberry 2. Presence of major diseases, with pharmacological treatments

Design outcomes

Primary

Measure	Time frame
Phase I: polyphenols and salicylates measured through high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC-MS) analysis before and after intake at 1 h, 1,5 h, 2 h and 4 h Phase II: reactive hyperaemia markers (i.e. Reactive Hyperaemia Index (RHI) and Framingham RHI) and arterial stiffness markers (Augmentation Index (AI) and AI@75) measured through non-invasive EndoPAT 2000 device before and after intake at 2 h	—

Measure

Time frame

Phase I: polyphenols and salicylates measured through high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC-MS) analysis before and after intake at 1 h, 1,5 h, 2 h and 4 h Phase II: reactive hyperaemia markers (i.e. Reactive Hyperaemia Index (RHI) and Framingham RHI) and arterial stiffness markers (Augmentation Index (AI) and AI@75) measured through non-invasive EndoPAT 2000 device before and after intake at 2 h

—

Secondary

Measure	Time frame
1. Systolic and diastolic blood pressure measured through a sphygmomanometer following standard procedure before and after intake at 2 h 2. Plasma levels of glucose and insulin evaluated through routine laboratory clinical assessment before and after intake at 1 h, 1,5 h, 2 h and 4 h 3. DNA damage evaluated through the comet assay before and after intake at 1 h, 1,5 h, 2 h and 4 h 4. Vascular function markers (e.g. nitric oxide, endothelin-1, VEGF, VCAM-1, ICAM-1) and inflammation markers (e.g. IL-6, IL-8, TNF-alpha) evaluated using an enzyme-linked immunosorbent assay (ELISA) kit before and after intake at 1 h, 1,5 h, 2 h and 4 h	—

Measure

Time frame

1. Systolic and diastolic blood pressure measured through a sphygmomanometer following standard procedure before and after intake at 2 h 2. Plasma levels of glucose and insulin evaluated through routine laboratory clinical assessment before and after intake at 1 h, 1,5 h, 2 h and 4 h 3. DNA damage evaluated through the comet assay before and after intake at 1 h, 1,5 h, 2 h and 4 h 4. Vascular function markers (e.g. nitric oxide, endothelin-1, VEGF, VCAM-1, ICAM-1) and inflammation markers (e.g. IL-6, IL-8, TNF-alpha) evaluated using an enzyme-linked immunosorbent assay (ELISA) kit before and after intake at 1 h, 1,5 h, 2 h and 4 h

—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 10, 2026